AI-guided dosing study for advanced liver cancer patients
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 study tests whether an artificial intelligence tool can help doctors choose the right dose for treating advanced hepatocellular carcinoma (HCC), a type of liver cancer. It aims to improve safety and effectiveness by matching treatment to you using your liver function, lab results, and treatment course.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older.
- Have advanced liver cancer confirmed by biopsy or a specific imaging result (LI-RADS 5).
- Have already tried treatments meant to target the cancer locally (surgery or locoregional therapy) but the cancer wasn’t eligible for cure by those, or it continued/progressed afterward.
- Have not more than one other active cancer at the same time (unless it won’t interfere with study treatment).
- Your body’s function should be fairly preserved (ECOG 2 or less) and your liver function should be in the Child-Pugh A category.
- Be able to do study follow-up for at least 12 weeks, have enough measurable tumor areas on scans, and meet blood/liver/kidney lab thresholds (including platelets, hemoglobin, INR, albumin, bilirubin, and liver enzymes).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
This study uses artificial intelligence to look at your liver cancer's environment and predict how well it might respond to a combination treatment called TACE (which blocks blood flow to the tumor) plus immunotherapy and targeted therapy. It aims to help personalize your care by better understanding your tumor.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This trial uses artificial intelligence to help doctors better stage (classify the severity of) and plan treatment for hepatocellular carcinoma, a type of primary liver cancer. Researchers will collect your clinical information and imaging to see if AI can improve decision-making about your care.
This study uses artificial intelligence to look at tumor samples and MRI scans from people with advanced liver cancer to help choose the best treatment. It aims to make treatment more personalized and effective.
This study uses an artificial intelligence (AI) tool to help doctors choose the best first-line immunotherapy for your liver cancer. It aims to see if the AI's recommendation improves treatment outcomes compared to standard selection.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.